US Attorney scrutinizes Copaxone marketing

Share this article:

The US Attorney's Office for the Southern District of New York is looking into how Teva marketed its MS drug Copaxone and Parkinson's medication Azilect since 2006. The Associated Press reports that the drugmaker announced the investigation Monday and is exploring “possible violations of the False Claims Act.” Citi research analyst Liav Abraham told the AP that the FDA has increased its False Claims investigations over the past few years and that they can take several years to wrap.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.